ALEXANDRIA, Va.— The American Society of Clinical Oncology (ASCO) and CancerLinQ LLC will join Vice President Joe Biden and other leaders in the cancer community for the Cancer Moonshot Summit at Howard University, on June 29, to launch new collaborations and exchange ideas on solving the complexities of cancer care. The Summit is designed to foster the formation of new alliances and actions that will expand the bounds of innovation and accelerate the prevention, diagnosis, and treatment of cancer.
ASCO will be represented by ASCO Chief Executive Officer Clifford A. Hudis, MD, FASCO, and CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick who will discuss the society’s perspective on speeding the discovery of new cancer treatments, including issues related to enrollment in clinical trials, access to care, federal funding, enhanced data sharing, and information technology and interoperability.
“With the rapid expansion of new cancer science, diagnostic tests, and treatments, there is an urgent need to break down barriers that impede progress in our fight against cancer—something that the Vice President clearly understands,” said Dr. Hudis. “We applaud Vice President Biden for his unparalleled leadership and for bringing together such a diverse group of stakeholders for this robust discussion.”
ASCO has been an active participant in the Cancer Moonshot Initiative and joined Vice President Joe Biden at the formal launch of the moonshot earlier this year. Since then, ASCO has discussed with the Vice President’s office research and policy proposals to advance discovery in cancer treatment, and the importance of big data initiatives, such as CancerLinQ—ASCO’s big data, rapid-learning system deployed in oncology practices across the United States—working to improve the quality of care for people with cancer as well as its strategic role in creating coalitions to encourage collaboration and convene the entire cancer community.
The Vice President spoke at ASCO’s 2016 Annual Meeting, challenging attendees to expand data sharing and increase the use of team-based approaches that harness different medical and scientific disciplines. In response to the National Cancer Institute’s request, ASCO will be submitting formal recommendations to the Blue Ribbon Panel on the Cancer Moonshot later this week.
Stay tuned to ASCO in Action for ongoing updates on the National Cancer Moonshot Initiative.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube. Cancer-related policy developments can be found at ascoaction.asco.org.
About CancerLinQ LLC:
CancerLinQ LLC is a subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of the CancerLinQ™ initiative. CancerLinQ™ is a health information technology (HIT) platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit www.cancerlinq.org.